Under normal conditions, "vaccines generate a response through pneumococcus-specific IgG antibodies. However, in patients ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer antibody company.” Both companies are focused on immunoglobulin antibodies, with ...

so both IgA and IgG should be used along with total IgA to determine whether there is an IgA deficiency. AGA: Antigliadin antibody; Anti-tTG: Autoantibodies against the transglutaminase protein ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

Transcutaneous immunization, a topical vaccine application, combines the advantages of needle-free delivery while targeting the immunologically rich milieu of the skin. In animal studies, this ...

Under normal conditions, "vaccines generate a response through pneumococcus-specific IgG antibodies. However, in patients with IgA deficiency, the lack of IgA reduces the vaccine's effectiveness", ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

Data from a Phase I trial found it to be safe and well tolerated with early signs of clinical activity EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody with IND-enabling studies underway ...